Navigation Links
World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition

or (650) 571-7400.

DoveBid and the DoveBid logo are registered trademarks of DoveBid, Inc.

Contacts Americas: Asia Pacific: Europe/Middle East/Africa: Josh Prince
+1.650.377.2604
jprince@dovebid.com DoveBid, Inc.
10877 Wilshire Boulevard, Suite 600
Los Angeles, CA 90024, United States
Tel +1.310.775.6700
Fax +1.310.775.6800 DoveBid Singapore Pte Ltd
38 Mosque Street, Singapore 059518
Tel +65.63344266
Fax +65.63340469 DoveBid Trading France SARL
60 rue Marcel Dassault
92100 Boulogne Billancourt, France
Tel +33.(0).1.55.20.06.10
Tel +33.(0).1.55.20.06.11


back to top
'"/>

Source:


Page: All 1 2 3

Related biology technology :

1. Preserve Samples for RNA Expression Microarrays RNAlater Around the World
2. RNAlater Around the World: The Art of Processing Difficult Samples
3. The Worlds Best DNase Improved TURBO DNA-free
4. RNase Activity in Mouse Tissue: Classification, Hierarchy, and Methods for Control
5. Advantages of Roche Applied Science amplification products
6. Tools for Proteomic Science II
7. Exploiting the Life Science Data Explosion to Speed New Drug Discovery
8. Automation of the Eppendorf Perfectprep BAC 96 DNA Kit on the Caliper Life Sciences Sciclone ALH 3000
9. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
10. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
11. National Instruments DIAdem -- Complete Your Technical Data Management Framework with Powerful Off-line Analysis, Visualization, and Report Generation
Post Your Comments:
Other Biology Technology:Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 2Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 3Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 4Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 5Genmab Discloses Target and Development Plans for HuMax-Inflam 2Genmab Discloses Target and Development Plans for HuMax-Inflam 3New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 2New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 3New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA 4